Navigation Links
Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
Date:12/11/2008

, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase II sarcoma clinical trial and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-lookin
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Inc. (Amex: ADL ), today announced the promotion ... (COO) and CFO. The Company is also,expanding its management ... of International Marketing and Sales and Mr. Raymond Gatchalian ... and CFO, Mr. Ariura will lead the day-to-day operations ...
... SNDY) is pleased to announce that the Company has ... St. Mary,s,Hospital in Waterbury, CT. St. Mary,s has been ... it has chosen to continue using the,Company,s surgical products., ... in the history of Greater,Waterbury, providing nearly a century ...
... CHICAGO, Nov. 6 Advanced Life Sciences,Holdings, Inc. ... in the,discovery, development and commercialization of novel drugs ... diseases, today,announced its financial results for the third ... ), The net loss available to common ...
Cached Biology Technology:AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team 2AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team 3AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team 4Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Advanced Life Sciences Announces Third Quarter 2008 Financial Results 2Advanced Life Sciences Announces Third Quarter 2008 Financial Results 3Advanced Life Sciences Announces Third Quarter 2008 Financial Results 4Advanced Life Sciences Announces Third Quarter 2008 Financial Results 5Advanced Life Sciences Announces Third Quarter 2008 Financial Results 6Advanced Life Sciences Announces Third Quarter 2008 Financial Results 7Advanced Life Sciences Announces Third Quarter 2008 Financial Results 8Advanced Life Sciences Announces Third Quarter 2008 Financial Results 9Advanced Life Sciences Announces Third Quarter 2008 Financial Results 10Advanced Life Sciences Announces Third Quarter 2008 Financial Results 11
(Date:4/17/2014)... deforestation and fragmentation of forests in the Amazon ... forests, contributing to rapid and widespread forest loss ... researchers., The findings show that forests in the ... droughts coupled with forest fires lead to large-scale ... Jennifer Balch, assistant professor of geography, Penn State. ...
(Date:4/17/2014)... new early-warning signs of the potential loss of sight ... for the diagnosis and treatment of diabetic retinopathy, potentially ... "We had not expected to see such striking changes ... Elsner, professor and associate dean in the IU School ... set out to study the early signs, in volunteer ...
(Date:4/17/2014)... the Australian National University (ANU), have developed a ... temperature variability over the past 5.3 million years., ... climate surrounding ice ages over the past two ... between carbon dioxide levels, global temperatures and sea ... Southampton (UoS) and the National Oceanography Centre (NOC) ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Ancient sea-levels give new clues on ice ages 2
... new eco-friendly way of dissolving wood using ionic liquids ... as bio fuels, textiles, clothes and paper. Dr ... School of Chemistry and Chemical Engineering worked along with ... with a more cost and energy efficient way of ...
... recent rapid growth of institutional Memberships for open ... introduction of the "Online Reporting System" for its ... on BioMed Central,s cutting edge publishing platform, the ... budgeting and help reduce the administrative costs associated ...
... presentation, “New Strategies for Optimizing CHO Performance,” to ... called ZAP-CHO during BIO 2009 International Convention in ... 2009 / b3c newswire / – InVitria’s ... present the performance enhancing features of ZAP-CHO, a ...
Cached Biology News:Queen's scientists discover eco-friendly wood dissolution 2InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO 2
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Biology Products: